Analysis of Cyclophilin A Levels in Subarachnoid Hemorrhage Patients

Devin Patel
Washington University in St. Louis

Follow this and additional works at: https://openscholarship.wustl.edu/wushta_spr2018

Recommended Citation
https://openscholarship.wustl.edu/wushta_spr2018/97

This Abstract for College of Arts & Sciences is brought to you for free and open access by the Washington University Senior Honors Thesis Abstracts at Washington University Open Scholarship. It has been accepted for inclusion in Spring 2018 by an authorized administrator of Washington University Open Scholarship. For more information, please contact digital@wumail.wustl.edu.
Subarachnoid hemorrhage (SAH), a unique form of hemorrhagic stroke, remains a serious health problem with a 30% mortality rate in the United States. Of those surviving the initial hemorrhage, more than half deteriorate in the days following SAH due to delayed cerebral ischemia (DCI) and early brain injury (EBI). The predominant vascular deficit leading to EBI is blood-brain barrier (BBB) disruption, along with the release of cytotoxic agents and inflammatory mediators. Recently, a causal link between metalloprotease 9 (MMP9) and EBI after SAH has been suggested in rodent studies. A correlation between serum MMP9 levels and vasospasm in human SAH has also been noted. While a major contributing role of MMP9 in SAH-induced brain injury is rapidly being established, the upstream molecular events leading to its upregulation and the downstream molecular events by which it causes EBI are poorly understood. Cyclophilin A (CypA) is a proinflammatory molecule that is known to drive MMP9 expression via the transcription factor NF-κB p65. Previously we discovered that CypA plays a causal role in AD-induced cerebrovascular deficits, including APOE4-linked BBB disruption and CBF deficits. CypA is secreted from cells in response to inflammatory stimuli, such as hypoxia and oxidative stress. Whether CypA plays a role in EBI and DCI following SAH, however, is not known. Our key goal is to identify if CypA levels increase in SAH patients and are involved in DCI and EBI. We hypothesize that reactive oxygen species (ROS) released by hypoperfusion and the degradation of hemoglobin stimulate the secretion of significant amounts of CypA, which contributes to neurological and cerebral dysfunction. Furthermore, we hypothesize a prevalent role of CypA in DCI, EBI, and poor clinical outcome and therefore hope to identify CypA as a therapeutically targetable molecule.